Alexion Pharmaceuticals (ALXN) Earns Daily Media Impact Score of 0.20
Media headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.9756719515164 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Teva/Nuvelution to Speed Up Development of Austedo in US (finance.yahoo.com)
- ProQR's Genetic Disorder Candidate Gets Orphan Drug Status (finance.yahoo.com)
- Novartis Poised to Grow on Oncology Portfolio & Biosimilars (finance.yahoo.com)
- Alexion Pharmaceuticals : Adds Paul A. Friedman, M.D. To Its Board of Directors (4-traders.com)
- Pluristem's Ischemia Candidate Gets Fast Track Designation (finance.yahoo.com)
Several analysts recently weighed in on ALXN shares. Morgan Stanley raised Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $101.08 to $138.00 in a research note on Thursday, May 25th. Cowen and Company reaffirmed an “outperform” rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. J P Morgan Chase & Co lowered Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, May 23rd. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $157.13.
Shares of Alexion Pharmaceuticals (ALXN) traded up 0.06% during midday trading on Wednesday, reaching $142.92. The company’s stock had a trading volume of 1,407,545 shares. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a market capitalization of $31.90 billion, a P/E ratio of 61.98 and a beta of 1.40. The company’s 50-day moving average price is $139.14 and its 200 day moving average price is $124.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. The business had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.13 EPS. On average, equities research analysts forecast that Alexion Pharmaceuticals will post $5.60 earnings per share for the current year.
In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the transaction, the executive vice president now owns 26,092 shares of the company’s stock, valued at approximately $3,794,820.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold a total of 17,070 shares of company stock valued at $2,416,869 in the last ninety days. 4.35% of the stock is currently owned by corporate insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.